AI assistant
ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2024
Jan 8, 2024
31071_dirs_2024-01-08_97d0ca1a-16c2-4419-a68a-c9a1090d9b6e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2024-01-04
Reporting Person: Oliver Tracie (Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-01-04 | Common Stock | A | 75000 | — | Acquired | 136575 | Direct |
| 2024-01-05 | Common Stock | S | 74 | $33.89 | Disposed | 136501 | Direct |
Footnotes
F1: Represents shares underlying restricted stock units with a grant date 01/04/24, which will vest in four equal annual installments.
F2: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F3: Partial disposition of RSUs to satisfy tax withholding obligations.
F4: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.